 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Halozyme Therapeutics, Inc. (HALO) operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. 
The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents.
The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders.
In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody.
The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV.
Shares are heading higher in an upward trading channel following its latest quarterly report. On November 8th, HALO reported 3rd Quarter September 2022 earnings of $0.70 per share on revenue of $209.0 million. The consensus earnings estimate was $0.49 per share on revenue of $186.3 million. Revenue grew 80.4% on a year-over-year basis.
Guided Higher: The company said it continues to expect 2022 non-GAAP earnings of $2.10 to $2.25 per share on revenue of $655.0 million to $685.0 million. The current consensus earnings estimate is $2.14 per share on revenue of $656.53 million for the year ending December 31, 2022.
Entry Point: $56.50
Trading Range: $31.36 to $59.46
Stop Loss: $53.00
Target Price: $61.80
